ClinicalTrials.gg
Active, not recruitingNCT06388083DRAGON IIUpdated Mar 12, 2026

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

A Phase 2/3 interventional study of Tinlarebant and Placebo in STGD1 and Stargardt Disease 1, sponsored by Belite Bio, Inc. Active, not recruiting at 18 sites in 3 countries. Open to participants aged 12 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Belite Bio, Inc · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
12 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Stargardt Disease with a site in United States — 16 open to participants now, 25 under way, 3 of them phase 3. Stargardt Disease · United States.

Planned enrollment
10th of 26
60 · median 41
Started
2024
with 5 others
Phase 2/3
2 of 42
none open now
Primary completion
2028-02
later than 9 of 24 live
Registered
29th of 42
by date
Lead sponsor
2 of 42
Belite Bio, Inc

Among the 42 studies in Stargardt Disease with a site in United States, this one is the 10th largest by planned enrollment of the 26 interventional ones that give a count, is one of 6 that started in 2024, is one of 2 in phase 2/3, reaches primary completion later than 9 of the 24 other live ones, and was the 29th registered.

Stargardt Disease

68 studies on the registry are indexed under Stargardt Disease; 27 are open to participants now.

Browse Stargardt Disease studies →

Open to participants now

16 of the 42 studies in Stargardt Disease with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Stargardt Disease studies recruiting now, 15 (63%) set no upper age limit and 7 (29%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.

This study: 12 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Stargardt Disease with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease

Read the detailed description

This study will be comprised of a Phase 1b part conducted in Japan and a Phase 2/3 part. The Phase 1b part of the study will be open-label and will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of daily doses of 5 mg tinlarebant, administered for 7 days, in Japanese subjects with Stargardt Disease (STGD1). The Phase 2/3 part of the study will be randomized, double masked, and placebo controlled to evaluate the safety, tolerability, and efficacy of daily doses of 5 mg tinlarebant, administered for 24 months, in subjects with STGD1.

03

Conditions studied

  • STGD1
  • Stargardt Disease 1

Browse trials for

04

Who can participate

Ages eligible
12 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have clinically diagnosed STGD1 with at least one mutation identified in the ABCA4 gene.
  • Subjects must have a defined aggregate atrophic lesion in 1 or both eyes.
  • Minimum BCVA is required in the study eye

Exclusion criteria

Exclusion Criteria:

  • Any ocular disease other than STGD1 that, in the opinion of the investigator, would complicate assessment of a treatment effect.
  • History of ocular surgery in the study eye in the last 3 months.
  • Any prior gene therapy.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    LBS-008, Tinlarebant

    5 mg tablet taken orally once a day

    Drug: Tinlarebant

  • Placebo comparator
    Placebo

    Placebo tablets for tinlarebant 5 mg prepared similarly

    Drug: Placebo

Interventions

  • 5 mg tablet

    Also known as: LBS-008

  • DrugPlacebo

    Placebo tablets

06

What researchers measure

Primary outcomes

  1. To measure the annualized rate of change from baseline lesion size in aggregate area of atrophy

    Time frame: From baseline to Month 24

Secondary outcomes

  1. To measure the annualized rate of change in total area of atrophy

    Time frame: From baseline to Month 24

  2. Change in BCVA measured by the ETDRS method

    Time frame: From baseline to Month 24

07

Study locations

18 sites
  • Belite Study Site - US08
    Phoenix, Arizona 85020, United States
  • Belite Study Site - US05
    La Jolla, California 92093, United States
  • Belite Study Site - US09
    San Francisco, California 94158, United States
  • Belite Study Site - US06
    Miami, Florida 33136, United States
  • Belite Study Site - US01
    Boston, Massachusetts 02115, United States
  • Belite Study Site - US11
    Edina, Minnesota 55435, United States
  • Belite Study Site - US04
    Rochester, Minnesota 55905, United States
  • Belite Study Site - US14
    New York, New York 10032, United States
  • Belite Study Site - US10
    Westbury, New York 11590, United States
  • Belite Study Site - US02
    Durham, North Carolina 27705, United States
  • Belite Study Site - US07
    Philadelphia, Pennsylvania 19107, United States
  • Belite Study Site - US13
    Austin, Texas 78705, United States
  • Belite Study Site - US03
    Dallas, Texas 75231, United States
  • Belite Study Site - US12
    The Woodlands, Texas 77384, United States
  • Belite Study Site
    Kobe, Japan
  • Belite Study Site
    Kyoto, Japan
  • Belite Study Site
    Tokyo, Japan
  • UK01 Belite Study Site
    London, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Feb 2028, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2024
First posted
Apr 29, 2024
StartActual
Jul 31, 2024
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06388083
Lead sponsor
Belite Bio, Inc
Responsible party
Sponsor
First posted
Apr 29, 2024
Start date
Jul 31, 2024
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Mar 12, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tinlarebant

Start the discussion